Alvotech, a global biotech company, has announced the acquisition of Ivers-Lee Group, a Switzerland-based provider of assembly and packaging services for the pharmaceutical sector.
This strategic move is set to enhance Alvotech’s capacity in the assembly and packaging of biosimilar medicines.
Go deeper with GlobalData
Founded in 1947 in Burgdorf, Switzerland, Ivers-Lee has established itself as a provider of high-quality packaging services.
With a good manufacturing practice-licensed and Food and Drug Administration-approved site in Burgdorf and a strategic business unit in Lörrach, Germany, Ivers-Lee’s capabilities will be integrated into Alvotech’s Technical Operations division.
This integration will include the assembly and packaging of auto-injectors, prefilled syringes, safety devices, and vials.
Ivers-Lee’s managing director Peter Schüpbach will continue in his role while also joining Alvotech’s Technical Operations senior leadership team.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSchüpbach said: “Alvotech offers the Ivers-Lee Group financial strength and development opportunities in a growth market, that we as a founding family cannot offer. This change brings stability both for Ivers-Lee and its employees.”
Post-deal, Ivers-Lee will maintain its international customer base and continue to offer contract manufacturing services, including blister and stick-pack activities, clinical supplies, and QP services from its Lörrach unit.
The expansion of Alvotech’s operations is poised to strengthen its position in the global pharmaceutical market.
Alvotech founder, chair, and CEO Robert Wessman said: “Ivers-Lee has been an Alvotech preferred partner in assembly and packaging for several years. We know and trust each other very well, having worked closely together.
“As Alvotech prepares for the launch of three new biosimilars in 2025 and sales growth in global markets, the integration of Ivers-Lee into our Technical Operations, provides added flexibility and capacity to meet increased global demand for our biosimilars, maintaining the highest level of quality and service.”
